Note 14 — Net Income (Loss) Per Share

The Net income (loss) per share - attributable to PAVmed - basic and diluted and Net income (loss) per share - attributable to PAVmed common stockholders - basic and diluted - for the respective periods indicated - is as follows:

The common stock equivalents that have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive are as follows:

The Series B Convertible Preferred Stock dividends earned as of each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors.

Basic weighted-average number of shares of common stock outstanding for the three and six months ended June 30, 2026 and 2025 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for the three and six months ended June 30, 2026, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

The total stock options are inclusive of 1,446 and 1,816 stock options as of  June 30, 2026 and 2025, respectively, granted outside the PAVmed 2014 Equity Plan.